CIDRAP newsletters options
High-incidence jurisdictions now report cases based on lab results alone rather than lab data plus clinical information.
Researcher says ongoing surveillance is needed to ensure that women receive optimal empiric antibiotics for uncomplicated UTIs.
Both controls and cases in the trial had an approximate mortality rate of 15% at day 90.
After 55% of a prison population agreed to be immunized, no further cases were detected.
Preterm infants accounted for 25% of RSV-associated hospitalizations.
Average weekly outgoing transfers per hospital stayed lower than the prepandemic average of 12 transfers per week for most of the pandemic.
Nationally, 6.4% of US adults reported ever having experienced long COVID
The updated guidelines will be released later this year.
The results of a phase 3 trial suggest cefepime-taniborbactam is a treatment option for patients with complicated UTIs caused by difficult-to-treat, gram-negative bacteria.
MERS-CoV antibody reactivity was identified in 7 of 48 camel-slaughterhouse workers (15%).
Treatment shortened symptoms by a day and also reduced viral loads.
Having tools to identify outbreaks early is crucial for containing outbreaks for both dangerous pathogens.
57% of those with post–COVID-19 condition—or long COVID—said they experienced symptoms of a cognitive (thinking) deficit daily.
Oral cholera vaccine shortages are still critical, with the global stockpile depleted.
Unlike reverse transcription-polymerase chain reaction, rapid antigen tests are still subject to misinterpretation by both patients and clinicians.
European health officials say the rise in Klebsiella pneumoniae strains combining hypervirulence with resistance to last-resort antibiotics is a cause for concern.
At least half of US adults hospitalized with uncomplicated community-acquired pneumonia in 2020 received 7 days or more of antibiotics.
Girls (43%) were more likely than boys (35%) to have received one or more HPV vaccine doses.
Sensitivity was 99% for all patients and 100% in the people affected by HIV.
The vaccine campaign targets 610,000 people in South Sudan's Western Equatoria state.
